32,962 results match your criteria Graft Versus Host Disease


Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.

Transfusion 2020 Jul 3. Epub 2020 Jul 3.

Department of Blood Group Serology and Transfusion Medicine, Medical University Graz and LKH-Univ.Klinikum Graz, Graz, Austria.

Background: Pathogen reduction (PR) of platelet concentrates (PCs) contributes to the safety of platelet (PLT) transfusion by reducing the risk of transfusion-transmitted infections and transfusion-associated graft-versus-host disease. In vitro quality of pathogen-reduced double-dose PC (PR-PC) made of eight whole blood (WB)-derived buffy coats (BCs) were evaluated.

Methods: Eight small-volume WB BCs from donors with at least 200 × 10 PLT/L were pooled with an additive solution to produce double-dose PCs (DD-PCs), which were treated with amotosalen/ultraviolet A light in a dual storage processing set, yielding 2 units of PR-PC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15926DOI Listing

Senescence-associated secretory phenotype promotes chronic ocular graft-vs-host disease in mice and humans.

FASEB J 2020 Jul 3. Epub 2020 Jul 3.

Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.

Chronic graft-vs-host disease (cGVHD) is a multifactorial inflammatory disease that affects patients undergoing hematopoietic stem cell transplantation. Multiple organs, including the lacrimal glands (LGs), are negatively affected by cGVHD and lose function due to the resultant fibrosis. An abnormal immune response is thought to be a major factor in the development of chronic ocular GVHD, which is currently treated primarily with immunosuppressive therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.201900218RDOI Listing

Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.

Pediatr Blood Cancer 2020 Jul 2:e28233. Epub 2020 Jul 2.

Department of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France.

Background: We conducted a national multicenter retrospective study in France to evaluate the efficacy and tolerance of ruxolitinib in children with steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplant.

Procedure: Patients were recruited from the 15 pediatric transplantation centers. Transplanted patients were eligible if they met the following criteria: aged ≤ 18 years at transplantation, receiving a myeloablative allogeneic hematopoietic stem cell transplant, having an aGVHD of grade ≥2, and treated with ruxolitinib for steroid-refractory aGVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28233DOI Listing

Injury intensifies T cell mediated graft-versus-host disease in a humanized model of traumatic brain injury.

Sci Rep 2020 Jul 1;10(1):10729. Epub 2020 Jul 1.

Children's Regenerative Medicine Program, Department of Pediatric Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.

The immune system plays critical roles in promoting tissue repair during recovery from neurotrauma but is also responsible for unchecked inflammation that causes neuronal cell death, systemic stress, and lethal immunodepression. Understanding the immune response to neurotrauma is an urgent priority, yet current models of traumatic brain injury (TBI) inadequately recapitulate the human immune response. Here, we report the first description of a humanized model of TBI and show that TBI places significant stress on the bone marrow. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67723-xDOI Listing

Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8.

Sci Transl Med 2020 Jul;12(550)

Department of Hematology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8638, Japan.

Graft-versus-host disease (GVHD) and infection are major obstacles to successful allogeneic hematopoietic stem cell transplantation (HSCT). Intestinal goblet cells form the mucus layers, which spatially segregate gut microbiota from host tissues. Although it is well known that goblet cell loss is one of the histologic features of GVHD, effects of their loss in pathophysiology of GVHD remain to be elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaw0720DOI Listing

Monocyte subsets in bone marrow grafts may contribute to a low incidence of acute graft-vs-host disease for young donors.

J Cell Mol Med 2020 Jun 30. Epub 2020 Jun 30.

Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Young donors are associated with a lower cumulative incidence of acute graft-vs-host disease (aGVHD) after allogenic haematopoietic stem cell transplantation (allo-HSCT) than old donors. Although grafts are harvested from healthy donors, it is unclear whether donor age is associated with aGVHD occurrence owing to its effect on cell compositions in grafts. Moreover, the differences in monocyte subsets in grafts between young and old donors and the association between monocyte subsets in bone marrow (BM) grafts and aGVHD remain to be elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.15557DOI Listing

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity.

Bone Marrow Transplant 2020 Jun 30. Epub 2020 Jun 30.

Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.

Myeloid sarcoma (MS) as a solid extra-medullary (EM) manifestation of acute myeloid leukemia (AML), myeloproliferative or myelodysplastic syndromes is a rare presentation of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). The databases of the Departments of Hematology and Oncology of the University Hospitals of Jena and Rostock were screened for patients aged 18 years or older for onset of MS after HSCT for myeloid malignancies between 2002 and 2019. Nineteen patients with MS were identified, the majority of whom had received reduced-intensity conditioning (RIC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0984-4DOI Listing

Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.

Transpl Infect Dis 2020 Jun 30:e13396. Epub 2020 Jun 30.

Shire, a Takeda company, Cambridge, MA, USA.

Background: In transplant recipients, cytomegalovirus (CMV) infection increases morbidity and mortality; furthermore, coinfection with other human herpesviruses like the Epstein-Barr virus (EBV) may complicate their management. This systematic literature review aimed to summarize rates of CMV-EBV coinfection and associated clinical outcomes among solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients.

Methods: An electronic literature search was performed using pre-specified search strategies (January 1, 2010-October 31, 2018) and following established/best practice methodology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.13396DOI Listing

Pericardectomy after pericarditis constrictiva led to onset of transplant kidney function after 98 days of anuric kidney graft: a case report.

BMC Nephrol 2020 Jun 29;21(1):241. Epub 2020 Jun 29.

Department of Nephrology and Hypertension, University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany.

Background: Constrictive pericarditis is easily overlooked and can lead to severe problems in hemodynamics and end-organ perfusion, in our patient leading to 98 days of anuria after living kidney transplantation. This was completely reversible after pericardectomy.

Case Presentation: A 43-year-old female caucasian patient received a living kidney donation from her mother. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-020-01899-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324971PMC

Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation.

Blood Adv 2020 Jul;4(13):2912-2917

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.

Oral mucositis (OM) is a common debilitating dose-limiting toxicity of cancer treatment, including hematopoietic stem cell transplantation (HSCT). We hypothesized that the oral microbiome is disturbed during allogeneic HSCT, partially accounting for the variability in OM severity. Using 16S ribosomal RNA gene sequence analysis, metabolomic profiling, and computational methods, we characterized the behavior of the salivary microbiome and metabolome of 184 patients pre- and post-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001827DOI Listing

Extracorporeal Photopheresis: A Case of Immunotherapy Ahead of Its Time.

Transfus Med Hemother 2020 Jun 27;47(3):226-235. Epub 2020 May 27.

Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.

Extracorporeal photopheresis (ECP) is a cell-based immunotherapy that involves the reinfusion of autologous leukocytes after exposure to psoralen and UVA. The treatment has been used for over 30 years, at first on patients with cutaneous T-cell lymphoma (CTCL) and later for the management of patients with graft-versus-host disease (GvHD), sclerosing disorders, atopic dermatitis, and other diseases that may share the common driving factor of a pathogenic T-cell clone or clones in blood circulation. Patients with clinical improvement mount an antigen-specific immune response that may have tolerance traits in the case of GvHD or anticlonal cytotoxic characteristics in the case of CTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508479DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315210PMC

Extracorporeal Photopheresis in Graft-versus-Host Disease.

Transfus Med Hemother 2020 Jun 19;47(3):214-225. Epub 2020 May 19.

Division of Hematology, University Hospital Basel, Basel, Switzerland.

Background And Summary: Extracorporeal photopheresis (ECP) is a leukapheresis-based procedure used in the therapy of acute and chronic graft-versus-host disease (aGvHD, cGvHD) and other diseases. Based on the substantial efficacy and the excellent safety profile in the absence of immunosuppression ECP has established itself as a major treatment form for steroid-refractory GvHD. Here we review the current literature on ECP as a treatment option for patients with aGvHD as well as cGvHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315199PMC

Oral graft-versus-host disease: a pictorial review and a guide for dental practitioners.

Int Dent J 2020 Jun 28. Epub 2020 Jun 28.

Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Introduction: Graft-versus-host disease (GVHD) is a complication of haematopoietic stem cell transplantation (HSCT). GVHD may also develop following solid transplants or blood transfusions if white blood cells are transferred. GVHD affects multiple organs, including the oral tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/idj.12584DOI Listing

Effects of Hormone Replacement Therapy on Bone Mass after Allogeneic Hematopoietic Stem Cell Transplantation.

J Clin Endocrinol Metab 2020 Jun 27. Epub 2020 Jun 27.

Division of Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Context And Objectives: This study aimed to assess the effects of hormone replacement therapy (HRT) on bone mineral density (BMD) in young females who underwent allogeneic hematopoietic stem cell transplantation (HSCT).

Participants And methods: The retrospective cohort included 234 female patients with premature ovarian insufficiency (POI) who underwent allogeneic HSCT between April 2009 and April 2016 at Seoul St. Mary's Hospital in Seoul, Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/clinem/dgaa406DOI Listing

Global Metabolomics in Allogeneic Hematopoietic Cell Transplant Recipients Discordant for Chronic Graft-versus-Host Disease.

Biol Blood Marrow Transplant 2020 Jun 24. Epub 2020 Jun 24.

College of Nursing, University of Florida, Gainesville, Florida, USA.

Background: Chronic graft-versus-host disease (cGVHD) remains a significant late effect issue for allogeneic hematopoietic cell transplantation survivors contributing to morbidity and mortality. The etiology of cGVHD is not well elucidated. Due to lack of early diagnostic tests and pathophysiology ambiguity, there remain limited targeted treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.014DOI Listing
June 2020
3.404 Impact Factor

Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: a Retrospective Cohort Study.

Biol Blood Marrow Transplant 2020 Jun 24. Epub 2020 Jun 24.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address:

Background: Immune checkpoint inhibitors (ICIs) are approved in relapsed classic Hodgkin lymphoma (cHL). The safety and effectiveness of allogeneic blood or marrow transplantation (alloBMT) in ICI pre-treated cHL patients remain unclear. The aim of this study is to assess outcomes of cHL patients receiving ICIs before alloBMT using post-transplantation cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.012DOI Listing

Cytokine release syndrome after allogeneic stem cell transplantation with post-transplant cyclophosphamide.

Hematol Oncol 2020 Jun 27. Epub 2020 Jun 27.

Hematology and Hemotherapy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies.The use of post-transplant cyclophosphamide (PTCy) as graft-vs-host disease (GVHD) prophylaxis in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has led to the extension of allogeneic HSCT to patients without HLA-identical donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2772DOI Listing

Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group.

Int J Hematol 2020 Jun 25. Epub 2020 Jun 25.

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Programmed death 1 ligand (PD-L1) is an immunomodulatory molecule expressed by cancer cells, and it has been widely demonstrated to inhibit host antitumor responses. The aim of the present study was to identify clinicopathological features associated with PD-L1 expression in the secondary solid cancers of patients after allogeneic hematopoietic stem cell transplantation. In this database of 530 patients who received allo-HSCT between 1990 and 2017, 15 developed solid cancers with a median interval of 3487 days after transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02926-6DOI Listing

H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect.

Front Immunol 2020 10;11:1163. Epub 2020 Jun 10.

Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for many types of hematological malignancies. Matching of donor and recipient for the major histocompatibility complex (MHC) improves the HSCT reconstitution, but donor-derived T cells reactive to non-MHC encoded minor histocompatibility antigens (MiHAs) can induce graft-versus-host disease (GVHD) while also being needed for graft-versus-leukemia (GVL) effects. MiHAs are allelically variant self-peptides presented conventionally on MHC molecules, but are alloantigenic in transplantation settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.01163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297985PMC

Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation.

Bone Marrow Transplant 2020 Jun 25. Epub 2020 Jun 25.

Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Hematology and Transplantation Unit, Paris, France.

Steroid-refractory graft versus host disease (GVHD) represents a fearsome complication after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a retrospective study on outcomes and risk factors associated with acute and chronic steroid-refractory GVHD in a large cohort of 1207 patients receiving HSCT in Saint Louis Hospital between 2007 and 2017. Among patients who developed an acute and/or a chronic GVHD, the cumulative incidences of acute and chronic steroid-refractory disease were 31% and 48%, respectively, at day +100 and 1-year post-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0977-3DOI Listing

ABO-Incompatible Kidney Transplantation After Bone Marrow Transplantation: A Case Report.

Transplant Proc 2020 Jun 22. Epub 2020 Jun 22.

Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Many studies have been made on ABO-compatible kidney transplants following hematopoietic stem cell transplantation. However, there have been few reports on ABO-incompatible kidney transplantation following hematopoietic stem cell transplantation (HSCT). We report on the case of a successful ABO-incompatible kidney transplantation with high titers after bone marrow transplantation experienced no infectious episodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2020.01.173DOI Listing

CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.

Stem Cell Res Ther 2020 Jun 26;11(1):254. Epub 2020 Jun 26.

Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpodae-ro, Seocho-gu, Seoul, 06591, South Korea.

Background: Human chronic graft-versus-host disease (CGVHD) shares clinical characteristics with a murine sclerodermatous GVHD (Scl-GVHD, B10.D2 → BALB/c) model that is characterized by skin and lung fibrosis. In this study, bone marrow- or adipose tissue-derived human mesenchymal stem cells (hMSCs) were injected into the Scl-GVHD mice to address their therapeutic effect on CGVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13287-020-01768-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318460PMC

Pharmacotherapy of oral mucosal manifestations of chronic graft-versus-host disease: When? What? and How?

Authors:
Yehuda Zadik

Expert Opin Pharmacother 2020 Jun 26:1-4. Epub 2020 Jun 26.

Faculty of Medicine, The Hebrew University of Jerusalem , Jerusalem, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2020.1763307DOI Listing

Challenges and Pitfalls in the Engineering of Human Interleukin 22 (hIL-22) Secreting .

Front Bioeng Biotechnol 2020 5;8:543. Epub 2020 Jun 5.

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States.

Engineered microbes for the delivery of intestinally directed therapeutics is a promising avenue for the treatment of various intestinal diseases including inflammatory bowel disease (IBD) and intestinal graft vs. host disease (GVHD). This modality of treatment would allow for the targeted delivery of therapeutics to the site of inflammation or disease while minimizing the systemic side effects that often accompany treatment of these pathologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fbioe.2020.00543DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289926PMC

Minor Histocompatibility Antigen-Specific T Cells.

Front Pediatr 2020 3;8:284. Epub 2020 Jun 3.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Minor Histocompatibility (H) antigens are major histocompatibility complex (MHC)/Human Leukocyte Antigen (HLA)-bound peptides that differ between allogeneic hematopoietic stem cell transplantation (HCT) recipients and their donors as a result of genetic polymorphisms. Some minor H antigens can be used as therapeutic T cell targets to augment the graft-vs.-leukemia (GVL) effect in order to prevent or manage leukemia relapse after HCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2020.00284DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283489PMC

T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies.

Front Pediatr 2020 9;8:282. Epub 2020 Jun 9.

The University of Arizona Cancer Center, Tucson, AZ, United States.

Twenty-one pediatric and young adult patients (1.1-24.7 years) with hematologic malignancies underwent myeloablative T-cell replete haploidentical bone marrow transplant (haplo-BMT) between October 2015 to December 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2020.00282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295947PMC

Enhancement of Antigen Presentation by Deletion of Viral Immune Evasion Genes Prevents Lethal Cytomegalovirus Disease in Minor Histocompatibility Antigen-Mismatched Hematopoietic Cell Transplantation.

Front Cell Infect Microbiol 2020 9;10:279. Epub 2020 Jun 9.

Institute for Virology and Research Center for Immunotherapy (FZI) at the University Medical Center of the Johannes Gutenberg-University of Mainz, Mainz, Germany.

Hematoablative treatment followed by hematopoietic cell transplantation (HCT) for reconstituting the co-ablated immune system is a therapeutic option to cure aggressive forms of hematopoietic malignancies. In cases of family donors or unrelated donors, immunogenetic mismatches in major histocompatibility complex (MHC) and/or minor histocompatibility (minor-H) loci are unavoidable and bear a risk of graft-vs.-host reaction and disease (GvHR/D). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fcimb.2020.00279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296086PMC

Insights Into the Role of Vitamin D as a Biomarker in Stem Cell Transplantation.

Front Immunol 2020 8;11:966. Epub 2020 Jun 8.

Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

Vitamin D was discovered 100 years ago and since then multiple studies have consistently proved its effect on bone health and mineral metabolism. Further research has also explored its so-called "non-classical" biological effects, encompassing immune regulation and control of cell proliferation and differentiation. Vitamin D downregulates pro-inflammatory immune cells and subsequently their cytokine production, while enhancing the anti-inflammatory subsets, thus mediating inflammation and fostering a more tolerogenic environment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.00966DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295104PMC

Immunotherapeutic effects of allogeneic mesenchymal stem cells on systemic lupus erythematosus.

Lupus 2020 Jul;29(8):872-883

NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, China.

Mesenchymal stem cells have been applied to treat graft versus host disease as they have immunosuppressive ability and can overcome the major histocompatibility complex-histocompatibility barrier. The potential of allogeneic mesenchymal stem cells in treating systemic lupus erythematosus (SLE) was investigated in this study. MRL/lpr mice which can develop acquired SLE-like phenotypes were selected as an animal model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320928419DOI Listing

Anti-IL-12/23 p40 antibody attenuates chronic graft-versus-host disease with lupus nephritis via inhibiting Tfh cell in mice.

Biomed Pharmacother 2020 Jun 21;129:110396. Epub 2020 Jun 21.

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China. Electronic address:

Systemic lupus erythematosus (SLE) is an autoimmune disease that is mainly caused by excessive accumulation of autoantibodies that target autoantibodies such as nucleic acids. T helper (Th) cell have been associated with the development of SLE. Typically, different subsets of Th cells secrete various cytokines to regulate the disease progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2020.110396DOI Listing

Endoscopic naso-biliary and -pancreatic duct drainage for refractory post-bulbar duodenal ulcer bleeding.

Dig Endosc 2020 Jun 23. Epub 2020 Jun 23.

Department of Hepatobiliary Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Bleeding peptic ulcer is usually manageable with endoscopic hemostasis and gastric acid suppressants; however, recurrent bleeding sometimes occurs, especially in patients with comorbidities . A woman in her 60s who had received bone marrow transplantation for mycosis fungoides 2 months earlier received 30 mg methylprednisolone for graft-versus-host disease (GVHD). She presented with anemia and melena, and emergency esophagogastroduodenoscopy (EGD) revealed a bleeding ulcer next to the peri-ampullary diverticulum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/den.13781DOI Listing

Eosinophilic gastroenteritis and graft-versus-host disease induced by transmission of Norovirus with fecal microbiota transplant.

Transpl Infect Dis 2020 Jun 23:e13386. Epub 2020 Jun 23.

Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Fecal microbiota transplantation (FMT) was performed to decolonize gastrointestinal tract from antibiotic-resistant bacteria before allogeneic hematopoietic cells transplantation (alloHCT). AlloHCT was complicated by Norovirus gastroenteritis, acute graft-versus-host-disease and eosinophilic pancolitis. Norovirus was identified in samples from FMT material. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.13386DOI Listing

Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study.

Stem Cells Transl Med 2020 Jun 23. Epub 2020 Jun 23.

Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Steroid-refractory chronic graft-vs-host disease (cGvHD) contributes to morbidity after allogeneic hematopoietic stem cell transplantation. Here, we report on 11 patients with severe, refractory cGvHD treated with repeated infusions of allogeneic bone marrow-derived mesenchymal stromal cells (MSC) over a 6- to 12-month period. Six patients responded to MSC treatment following National Institutes of Health response criteria, accompanied by improvement in GvHD-related symptoms and quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/sctm.20-0099DOI Listing

Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.

Clin Transplant 2020 Jun 23:e14018. Epub 2020 Jun 23.

University of Calgary, Calgary, AB, Canada.

Optimal conditioning and graft-vs-host disease (GVHD) prophylaxis for hematopoietic cell transplantation (HCT) are unknown. Here, we report on outcomes after low toxicity, myeloablative conditioning consisting of fludarabine, busulfan, and 4 Gy total body irradiation, in combination with thymoglobulin and post-transplant methotrexate and cyclosporine. We retrospectively studied 700 patients with hematologic malignancies who received blood stem cells from 7 to 8/8 HLA-matched unrelated or related donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ctr.14018DOI Listing

Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.

Ann Hematol 2020 Jun 22. Epub 2020 Jun 22.

Department of Hematology, Chinese PLA General Hospital, Beijing, 100853, China.

In allogeneic hematopoietic stem cell transplantation recipients, cytomegalovirus (CMV) infection can cause overt CMV-associated disease, which is a main cause of transplantation-associated mortality. CMV infection correlates closely with donor's type. We therefore examined whether risk factors of CMV reactivation and clinical endpoints in patients with hematologic malignancies after allogeneic peripheral blood stem cell transplantation (PBSCT) differed between using matched-sibling donors (MSD-SCT) and haploidentical donors (HID-SCT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04156-6DOI Listing

Development of CAR-T cell therapies for multiple myeloma.

Leukemia 2020 Jun 22. Epub 2020 Jun 22.

Department of Stem Cell Transplantation with Research Department Cell and Gene Therapy University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Currently available data on chimeric antigen receptor (CAR)-T cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) patients. The CAR-T field in MM is rapidly evolving with >50 currently ongoing clinical trials across all phases, different CAR-T design, or targets. Most of the CAR-T trials are performed in China and the United States, while European centers organize or participate in only a small fraction of current clinical investigations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0930-xDOI Listing

Allogeneic Transplantation for Myelofibrosis with Novel Graft-versus-Host Disease Prophylaxis.

Acta Haematol 2020 Jun 22:1-2. Epub 2020 Jun 22.

Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508198DOI Listing

Photodepletion with 2-Se-Cl prevents lethal graft-versus-host disease while preserving antitumor immunity.

PLoS One 2020 22;15(6):e0234778. Epub 2020 Jun 22.

Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America.

Acute graft-versus-host-disease (GVHD), limits the use of hematopoietic cell transplant (HCT) to treat a variety of malignancies. Any new therapeutic approach must satisfy three requirements: 1) Prevent GVHD, 2) Maintain anti-pathogen immunity, and 3) Maintain anti-tumor immunity. In prior studies we have shown that the selective photosensitizer 2-Se-Cl eliminates highly alloreactive lymphocytes from the graft prior to HCT preventing GVHD and that antiviral immune responses were preserved following incubation with 2-Se-Cl. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234778PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307732PMC

Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.

Cancer 2020 Jun 22. Epub 2020 Jun 22.

Harvard Medical School, Boston, Massachusetts.

Background: There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis.

Methods: We performed a retrospective analysis of melanoma patients at Dana-Farber Cancer Institute who received PD-1, CTLA-4, or combination ICIs between May 2011 to October 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32966DOI Listing

Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy.

Ann Transl Med 2020 May;8(9):584

Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan.

Background: Autologous chimeric antigen receptor (CAR) T cell therapy is a promising therapeutic strategy for treating hematologic malignancies. A spectrum of serious complications caused by CAR-T cells has caught great attention. We developed a novel CAR against CD19 namely UWC19, consisting anti-CD19 single-chain variable fragment (scFv) hinged with 4-1BB and CD3z signaling domains. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2020.02.148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290534PMC

Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC.

Ann Hematol 2020 Jun 20. Epub 2020 Jun 20.

Department of Hematology, CHU Hôtel Dieu, Place A. Ricordeau, 44093, Nantes Cedex, France.

Allogeneic stem cell transplantation (allo-SCT) represents the most beneficial treatment for patients with active relapsed/refractory (R/R) hematologic malignancies. Recently, sequential regimens combining debulking chemotherapy followed by reduced-intensity conditioning (RIC) have shown encouraging results for these patients. In this retrospective study, we report the extended results of a sequential regimen of clofarabine, cytosine arabinoside, and RIC in 131 adults with active R/R myeloid disease at transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04074-7DOI Listing

Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study.

Bone Marrow Transplant 2020 Jun 20. Epub 2020 Jun 20.

Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.

HLA haploidentical hematopoietic stem cell transplantation (HSCT), i.e., HSCT from a 1-HLA-haplotype-mismatched family donor, has been successfully performed even as a second transplantation for posttransplant relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0980-8DOI Listing

Hyposplenism, Hashimoto's Autoimmune Thyroiditis and Overlap Syndrome (Celiac Disease and Autoimmune Hepatitis Type 1).

Am J Med Sci 2020 Apr 25. Epub 2020 Apr 25.

"Carol Davila" University of Medicine and Pharmacy, "Sf. Ioan" Clinical Emergency Hospital, Gastroenterology Department, Bucharest, Romania.

Hyposplenism is associated with autoimmune diseases, inflammatory bowel disease, severe celiac disease, autoimmune thyroiditis, untreated HIV infection and chronic graft-versus-host disease. The aim of this study was to review the existing data on hyposplenism associated with celiac disease and Hashimoto's autoimmune thyroiditis. Our research was based on a clinical case concerning a 41-year-old female who presented with asthenia, fatigue, dyspepsia and chronic diarrhea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjms.2020.04.022DOI Listing

Heparin affects the induction of regulatory T cells independent of anticoagulant activity and suppresses the allogeneic immune responses.

Clin Exp Immunol 2020 Jun 19. Epub 2020 Jun 19.

Department of Immunology, Dokkyo Medical University School of Medicine, Kitakobayashi 880, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.

Heparin is a widely used anticoagulant that enhances antithrombin (AT) activity. However, heparin also suppresses immune and inflammatory responses in various rodent models and clinical trials, respectively. The mechanism by which heparin suppresses immune responses is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cei.13480DOI Listing

The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study.

Bone Marrow Transplant 2020 Jun 19. Epub 2020 Jun 19.

Sorbonne University, Paris, France.

A mismatched unrelated (MMUD) donor represents an alternative therapeutic option for patients who need allogeneic hematopoietic cell transplantation (allo-HCT) and do not have a human leukocyte antigen (HLA) matched donor. We studied outcomes of patients with acute leukemia transplanted from ≥2 HLA allele MMUD. The study population consisted of 465 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0974-6DOI Listing

Preconditioning absolute lymphocyte count and transplant outcomes in matched related donor allogeneic hematopoietic stem cell transplantation recipients with reduced-intensity conditioning and antithymocyte globulin treatment.

Biol Blood Marrow Transplant 2020 Jun 16. Epub 2020 Jun 16.

Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

The integration of antithymocyte globulin (ATG) has significantly reduced the incidence of graft-versus-host disease (GVHD) and is actively being used in allogeneic hematopoietic stem cell transplantation (allo-HSCT). The ATG dosage is determined by the recipient's body weight, but some insist that this approach does not reflect the actual target of ATG. In this respect, weight-based dosing may lead to ATG overdose, particularly in recipients with a relatively low absolute lymphocyte count (ALC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.005DOI Listing

[Indications and management of hematologic microtransplantation: Recommendations of the French Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)].

Bull Cancer 2020 Jun 16. Epub 2020 Jun 16.

Hôpital Huriez, CHRU de Lille, maladie du sang, 3, rue Michel-Polonowsky, 59000 Lille, France.

Microtransplantation (MT) is based on injection of HLA-mismatched G-CSF mobilized hematopoietic stem cells, in combination with chemotherapy but without use of conditioning regimen nor immunosuppressive drugs. As a result, a transient microchimerism is induced without engraftment. Its efficacy relies both on host immune system stimulation (recipient versus tumor) and on a graft versus tumor effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2020.03.016DOI Listing
June 2020
0.635 Impact Factor

Potential of Skin Microbiome, Pro- and/or Pre-Biotics to Affect Local Cutaneous Responses to UV Exposure.

Nutrients 2020 Jun 17;12(6). Epub 2020 Jun 17.

Research Unit for Photodermatology, Department of Dermatology, Medical University of Graz, 8010 Graz, Austria.

The human skin hosts innumerable microorganisms and maintains homeostasis with the local immune system despite the challenges offered by environmental factors such as ultraviolet radiation (UVR). UVR causes cutaneous alterations such as acute (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu12061795DOI Listing

Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia.

Int J Mol Sci 2020 Jun 16;21(12). Epub 2020 Jun 16.

Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main therapeutic strategy for patients with both malignant and nonmalignant disorders. The therapeutic benefits of allo-HSCT in malignant disorders are primarily derived from the graft-versus-leukemia (GvL) effect, in which T cells in the donor graft recognize and eradicate residual malignant cells. However, the same donor T cells can also recognize normal host tissues as foreign, leading to the development of graft-versus-host disease (GvHD), which is difficult to separate from GvL and is the most frequent and serious complication following allo-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21124281DOI Listing

Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation.

Support Care Cancer 2020 Jun 17. Epub 2020 Jun 17.

Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwandoro, Dong-gu, Ulsan, 44033, South Korea.

Purpose: The survival rates of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) have improved. However, HSCT can induce significant long-term complications. Therefore, we investigated the late complications and risk factors for quality of life (QOL) post-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-020-05572-0DOI Listing